Full Press Release Details
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update.
IDYA
IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
Key Takeaway: IDEAYA Biosciences Announces First Patient In for Phase 1 Trial of IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update